To describe primary care pharmacists’ current scope of practice in relation to laboratory testing.
Method:
A 2-tiered search of key databases (PubMed, EMBASE, MEDLINE) and grey literature with the following MeSH headings: prescribing, pharmacist/pharmacy, laboratory test, collaborative practice, protocols/guidelines. We focused on Canada, the United States, the United Kingdom, New Zealand and Australia for this review.
Results:
There is limited literature exploring primary care pharmacists’ scope of practice in relation to laboratory testing. The majority of literature is from the United States and Canada, with some from the United Kingdom and New Zealand and none from Australia. Overall, there is a difference in regulations between and within these countries, with the key difference being whether pharmacists access and/or order laboratory testing dependently or independently. Canadian pharmacists can access and/or order laboratory tests independently or dependently, depending on the province they practise in. US pharmacists can access and/or order laboratory tests dependently within collaborative practice agreements. In the United Kingdom, laboratory testing can be performed by independent prescribing pharmacists or dependently by supplementary prescribing pharmacists. New Zealand prescribing pharmacists can order laboratory testing independently. Most publications do not report on the types of laboratory tests used by pharmacists, but those that do predominantly resulted in positive patient outcomes.
Discussion/Conclusion:
Primary care pharmacists’ scope of practice in laboratory testing is presently limited to certain jurisdictions and is often performed in a dependent fashion. As such, a full scope of pharmacy services is almost entirely unavailable to patients in the United States, the United Kingdom, New Zealand and Australia. Just as in the case for pharmacists prescribing, evidence indicates better patient outcomes when pharmacists can access/order laboratory tests, but more research needs to be done alongside the implementation of local guidelines and practice standards for pharmacists who practise in that realm. Patients around the world deserve to receive a full scope of pharmacists’ practice, and lack of access to laboratory testing is one of the major obstacles to this. Can Pharm J (Ott) 2019;152:xx-xx.
Get full access to this article
View all access options for this article.
References
1.
TsuyukiRTBeahmNPOkadaH, et al. Pharmacists as accessible primary health care providers: review of the evidence. Can Pharm J (Ott)2018;151(1):4-5.
2.
Al HarmarnehYNLambSDonaldM, et al. Pharmacist prescribing and care improves cardiovascular risk, but what do patients think? A substudy of the RxEACH study. Can Pharm J (Ott)2018;151(4):223-7.
3.
World Health Organization. The role of the pharmacist in the health care system. New Delhi (India): World Health Organization; 1994.
4.
KehrerJPJamesDE. The role of pharmacists and pharmacy education in point-of-care testing. Am J Pharm Educ2016;80(8):129.
5.
HowarthHJacksonSFitzmauriceK, et al. Report of health promotion and screening activities by community pharmacists. Hobart, Tasmania: Community Pharmacy Research Support Centre: A Collaboration of Australian Pharmacy Schools; 2005.
6.
World Health Organization. The role of the pharmacist in the health care system: the scope of pharmacy and the functions of pharmacists: hospital pharmacy. New Delhi (India): WHO Consultative Group; 1994.
7.
EmmertonLMarriottJBessellT, et al. Pharmacists and prescribing rights: review of international developments. J Pharm Pharm Sci2005;8(2):217–2.
8.
HerrierRNBoyceRWApgarDA. Pharmacist-managed patient-care services and prescriptive authority in the U.S. Public Health Service. Hosp Formul1990;25(1):67-8, 76-8, 80.
9.
Pharmaceutical Society of New Zealand Incorporated. New Zealand National Pharmacist Services Framework. Wellington: Pharmaceutical Society of New Zealand Incorporated; 2014.
10.
PearsonGJ. Evolution in the practice of pharmacy—not a revolution!CMAJ2007;176(9):1295-6.
11.
TonnaAPStewartDWestB, et al. Pharmacist prescribing in the UK: a literature review of current practice and research. J Clin Pharm Ther2007;32(6):545–5.
12.
YukselNEberhartGBungardTJ. Prescribing by pharmacists in Alberta. Am J Health Syst Pharm2008;65(22):2126-32.
13.
TsuyukiRTHouleSKDOkadaH. Time to give up on expanded scope of practice [Editorial]. Can Pharm J (Ott)2018;151(5):286-7.
The Conference Board of Canada. A review of pharmacy services in Canada and the health and economic evidence. Ottawa: Canadian Pharmacists Association; 2016.
16.
ScottDM. United States health care system: a pharmacy perspective. Can J Hosp Pharm2016;69(4):306–1.
17.
MolesRJStehlikP. Pharmacy Practice in Australia. Can J Hosp Pharm2015;68(5):418–2.
18.
WeeksGGeorgeJMaclureK, et al. Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care. Cochrane Database Syst Rev2016;11:CD011227.
19.
BussVHDeeksLSShieldA, et al. Analytical quality and effectiveness of point-of-care testing in community pharmacies: a systematic literature review. Res Social Adm Pharm2019;15(5):483–9.
20.
KoehlerTBrownA. Documenting the evolution of the relationship between the pharmacy support workforce and pharmacists to support patient care. Res Social Adm Pharm2017;13(2):280-5.
21.
CopeLCAbuzourASTullyMP. Nonmedical prescribing: where are we now?Ther Adv Drug Saf2016;7(4):165–7.
22.
Nova Scotia College of Pharmacists. Standards of practice: testing. Halifax: Nova Scotia College of Pharmacists; 2015.
23.
Alberta College of Pharmacists. Guidelines for pharmacists ordering laboratory tests and using laboratory data. Edmonton: Alberta College of Pharmacists; 2011.
24.
MacLeod-GloverN. An explanatory policy analysis of legislative change permitting pharmacists in Alberta, Canada, to prescribe. Int J Pharm Pract2011;19(1):70-8.
25.
MansellKEdmundsKGuirguisL. Pharmacists’ scope of practice: supports for Canadians with diabetes. Can J Diabetes2017;41(6):558–6.
26.
Saskatchewan College of Pharmacy Professionals. Policies, standards and guidelines for pharmacists in accessing, ordering, performing using or interpreting medical laboratory tests. Regina, Saskatchewan: Saskatchewan College of Pharmacy Professionals; 2015.
27.
LeungVTharmalingamSCooperJ, et al. Canadian community pharmacists’ use of digital health technologies in practice. Can Pharm J (Ott)2016;149(1):38-45.
28.
HawesEMMisitaCBurkhartJI, et al. Prescribing pharmacists in the ambulatory care setting: experience at the University of North Carolina Medical Center. Am J Health Syst Pharm2016;73(18):1425-33.
29.
HammondRWSchwartzAHCampbellMJ, et al. Collaborative drug therapy management by pharmacists—2003. Pharmacotherapy2003;23(9):1210-25.
30.
McBaneSEDoppALAbeA, et al. Collaborative drug therapy management and comprehensive medication management—2015. Pharmacotherapy2015;35(4):e39-50.
31.
HolleLMHarrisCSChanA, et al. Pharmacists’ roles in oncology pharmacy services: results of a global survey. J Oncol Pharm Pract2017;23(3):185–9.
32.
California Pharmacists Association. Guidelines for Pharmacists ordering and managing tests to ensure safe and appropriate medication therapy. 5th ed.Sacramento, CA: California Pharmacists Association; 2014.
33.
Pharmaceutical Society of Northern Ireland. Standards and guidance for pharmacist prescribers. Belfast, Northern Ireland: Pharmaceutical Society of Northern Ireland; 2013.
34.
MurawskiMVillaKRDoleEJ, et al. Advanced-practice pharmacists: practice characteristics and reimbursement of pharmacists certified for collaborative clinical practice in New Mexico and North Carolina. Am J Health Syst Pharm2011;68(24):2341-50.
35.
WoolfRLockeAPottsC. Pharmacist prescribing within an integrated health system in Washington. Am J Health Syst Pharm2016;73(18):1416-624.
36.
TallianKBHirschJDKuoGM, et al. Development of a pharmacist-psychiatrist collaborative medication therapy management clinic. J Am Pharm Assoc (2003)2012;52(6):e252-8.
37.
HillJDHillJMGentileNJ. A review of state pharmacist collaborative practice laws. Am J Health Syst Pharm2016;73(18):1467-72.
38.
BourneRSWhitingPBrownLS, et al. Pharmacist independent prescribing in critical care: results of a national questionnaire to establish the 2014 UK position. Int J Pharm Pract2016;24(2):104–1.
39.
National Association of Pharmacy Regulatory Authorities (NAPRA). National statistics: provincial and territorial statistics—pharmacists: National Association of Pharmacy Regulatory Authorities (NAPRA). 2019. Available: https://napra.ca/national-statistics (accessed June 20, 2019).
40.
Canadian Institute for Health Information (CIHI). Health workforce, 2018—data tables. Ottawa, ON: CIHI; 2018.
41.
Bureau of Labor Statistics. Occupational outlook handbook (pharmacists). Washington (DC): Office of Occupational Statistics and Employment Projections, US Department of Labor; 2019. Available: https://www.bls.gov/ooh/healthcare/pharmacists.htm?view_full#tab-3 (accessed June 20, 2019).
42.
GaitherCASchommerJCDoucetteWR, et al. 2014 National Pharmacist Workforce Survey. Minneapolis (MN): Pharmacy Workforce Center, Inc. (PWC); 2015.
43.
General Pharmaceutical Council (GPhC). Annual report: annual fitness to practice report and annual accounts 2015/16. London (UK): GPhC; 2016.
44.
General Pharmaceutical Council (GPhC). Registrant survey 2013: initial analysis. London (UK): GPhC; 2014.
45.
General Pharmaceutical Council (GPhC). Prescribers survey report. London (UK): GPhC; 2016.
46.
Pharmacy Council New Zealand. 2018 Workforce demographic report. Wellington: Pharmacy Council New Zealand; 2018.
47.
RaghunandanRTordoffJSmithA. Non-medical prescribing in New Zealand: an overview of prescribing rights, service delivery models and training. Ther Adv Drug Saf2017;8(11):349–6.
48.
Australian Health Practitioner Regulation Agency (AHPRA). 2017/18 Pharmacy Board of Australia—annual report summary. Melbourne: AHPRA; 2018.
49.
Health Workforce Australia. Australia’s health workforce series pharmacists in focus. Adelaide: Health Workforce Australia; 2014.
50.
Al HamarnehYNHemmelgarnBCurtisC, et al. Community pharmacist targeted screening for chronic kidney disease. Can Pharm J (Ott)2016;149(1):13-7.
51.
CooneyDMoonHLiuY, et al. A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial. BMC Nephrol2015;16:56.
52.
HeislerMHoferTPSchmittdielJA, et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial. Circulation2012;125(23):2863-72.
53.
HirschJDSteersNAdlerDS, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther2014;36(9):1244-54.
54.
IpEJShahBMYuJ, et al. Enhancing diabetes care by adding a pharmacist to the primary care team. Am J Health Syst Pharm2013;70(10):877–8.
55.
MagidDJOlsonKLBillupsSJ, et al. A pharmacist-led, American Heart Association Heart360 Web-enabled home blood pressure monitoring program. Circ Cardiovasc Qual Outcomes2013;6(2):157–6.
56.
McKinnonAJorgensonD. Pharmacist and physician collaborative prescribing: for medication renewals within a primary health centre. Can Fam Physician2009;55(12):e86-91.
57.
TsuyukiRTHouleSKCharroisTL, et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation2015;132(2):93-100.
58.
TsuyukiRTAl HamarnehYNJonesCA, et al. The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial. J Am Coll Cardiol2016;67(24):2846-54.
59.
AnayaJPRiveraJOLawsonK, et al. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm2008;65(19):1841-5.
60.
FarlandMZByrdDCMcFarlandMS, et al. Pharmacist-physician collaboration for diabetes care: the diabetes initiative program. Ann Pharmacother2013;47(6):781-9.
61.
OlsonKLDelateTRasmussenJ, et al. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management. Am J Manag Care2009;15(8): 497-503.
62.
VilleneuveJGenestJBlaisL, et al. A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ2010;182(5):447–5.
63.
TsuyukiRTRosenthalMPearsonGJ. A randomized trial of a community-based approach to dyslipidemia management: pharmacist prescribing to achieve cholesterol targets (RxACT Study). Can Pharm J (Ott)2016;149(5):283–9.
64.
YuJShahBMIpEJ, et al. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. J Manag Care Pharm2013;19(2):102–1.
65.
Royal Pharmaceutical Society of Great Britain. Clinical governance framework for pharmacist prescribers and organisations commissioning or participating in pharmacist prescribing (GB wide). London, UK: Royal Pharmaceutical Society of Great Britain; 2007.
66.
National Association of Pharmacy Regulatory Authorities (NAPRA). Model standards of practice for Canadian pharmacists. Ottawa, ON: NAPRA; 2009.
67.
FranklinBEFarlandMZThomasJ, et al. Pharmacoeconomic analysis of the diabetes initiative program: a pharmacist-physician collaborative care model. Ann Pharmacother2013;47(12):1627-34.
